Previous studies have reported that PIK3CA mutation confers resistance in colorectal cancer, lung cancer, and breast cancer (Wang et al., 2018; Shibata et al., 2009; Hanker et al., 2013). This evidence concerns the gene PIK3CA and lung carcinoma.